+
+
Stay Informed
TEER

TRICLIP™ TRANSCATHETER TRICUSPID VALVE REPAIR CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge repair offers a minimally invasive treatment option for patients with severe symptomatic tricuspid regurgitation (TR).

TEER

TRICLIP™ TRANSCATHETER TRICUSPID
VALVE REPAIR
CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge repair offers a minimally invasive treatment option for patients with severe symptomatic tricuspid regurgitation (TR).

INSPIRED BY PATIENTS. MADE POSSIBLE BY YOU.

TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. The bRIGHT study and TRILUMINATE™ Pivotal trial demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe tricuspid regurgitation (TR).2-6

Exceptional safety.*2,10
Life-changing impact.2,9,10

The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing tricuspid regurgitation.

Remarkable and sustained TR reduction2

TR grade (Core Lab)

 

  • Exceptional safety2,10 at 30 days

    98.3%

    FREEDOM
    FROM MAEs

    0.6%

    NEW PACEMAKER
    IMPLANTATION

    0%

    DEVICE THROMBUS

    99.4%

    SURVIVAL

    0%

    NONELECTIVE CV
    SURGERY FROM
    DEVICE-RELATED AE

    0%

    DEVICE EMBOLIZATION

  • Significant improvement in health-related quality of life2
  • Baseline population characteristics2

    71%

    OF PATIENTS HAD MASSIVE
    OR TORRENTIAL TR

    4.4±0.7cm

    TRICUSPID VALVE
    ANNULUS DIAMETER

    >35%

    OF PATIENTS WITH PRIOR
    MITRAL OR AORTIC VALVULAR INTERVENTION

    15%

    OF PATIENTS HAD A CRT, CRT-D, ICD,
    OR PERMANENT PACEMAKER

    *At 30 days

TRILUMINATE PIVOTAL TRIAL DATA CARD


Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
 

GET DATA CARD

Proven across a broad
range of anatomies7,8

The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.

Designed to maximize TR reduction7

TR grade (Core Lab)

 

  • Successfully treated a broad range of anatomies8
  • Proven durability backed by clinical data

    NYHA Functional Class7

    KCCQ - OS Score12

  • TriClip TEER demonstrated procedural success and an exceptional safety profile5

    HIGH PROCEDURAL
    SUCCESS

    99.0%

    Implant
    sucess rate

    SHORT
    DEVICE TIME
     

    76±39

    Minutes

    HIGH SAFETY
    PROFILE
     

    97.5%

    Freedom
    from MAEs
    at 30 days



    99.0% survival at 30 days

    0.2% TV reintervention

    0.0% embolization

     

bRIGHT STUDY DATA CARD


Get the latest data from the bRIGHT Study in a one-pager PDF format.
 

GET DATA CARD

Proven safety and effectiveness

The TRILUMINATE™ Trial demonstrated that TriClip TEER safely and effectively reduces TR and HF hospitalizations. 

93%

SURVIVAL
AT 1 YR3

100%

IMPLANT
SUCCESS4

91%

ACUTE PROCEDURAL
SUCCESS RATE4

0%

STROKE4

0%

CONVERSION TO
SURGERY4

  • Significant and durable TR reduction11

    Durable reduction in tricuspid regurgitation (TR)

  • Significant improvement in function and quality of life11

    Durable improvements in NYHA


    ≥10-point KCCQ-OS score improvement was observed in 50% of subjects at three years.11

  • Significant reduction in hospitalizations4

    Reduced hospitalization rate
     

TRILUMINATE TRIAL DATA CARD


Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
 

GET DATA CARD

MAT-2006556 v11.0 | Item approved for OUS use only.

References
  1. Data on file at Abbott.
  2. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
  3. von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
  4. Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
  5. Lurz P, Besler C, Schmitz T, et al. Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice. JACC. 2023;82(4):281-291.
  6. Nickenig G., Weber M., Lurz P., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394 (10213): 2002-2011.
  7. Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
  8. Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results with TriClip™ G4 from the bRIGHT Study Presented at PCR London Valves 2022.
  9. Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
  10. Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24,2023; San Francisco, CA; USA.
  11. Nickenig G. Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
  12. Lurz P. Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study. Presented at EuroPCR on May 14-17, 2024; Paris, France.
Abbott Logo

Follow Abbott

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v17.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+